{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:35:41Z","timestamp":1756463741274,"version":"3.44.0"},"reference-count":38,"publisher":"BMJ","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DTB"],"published-print":{"date-parts":[[2004,8]]},"abstract":"<jats:p>Until the early 1990s, first-line drug therapy for patients with acute schizophrenia was usually a traditional antipsychotic, such as haloperidol. As recently as 1997, we recommended that newer, so-called 'atypical' antipsychotic drugs, such as olanzapine and risperidone, should be reserved for patients unable to tolerate traditional drugs.1<jats:sup>,<\/jats:sup>2 Now, atypical antipsychotics are widely regarded as better than traditional drugs, being generally less likely to cause troublesome extrapyramidal effects or hyperprolactinaemia.3<jats:sup>,<\/jats:sup>4 Current atypical antipsychotics differ from one another in important respects. Here we consider how important differences in their unwanted-effect profiles may influence the choice between these drugs for patients with schizophrenia.<\/jats:p>","DOI":"10.1136\/dtb.2004.42857","type":"journal-article","created":{"date-parts":[[2008,7,18]],"date-time":"2008-07-18T16:15:40Z","timestamp":1216397740000},"page":"57-60","source":"Crossref","is-referenced-by-count":14,"title":["Which atypical antipsychotic for schizophrenia?"],"prefix":"10.1136","volume":"42","member":"239","published-online":{"date-parts":[[2004,8,1]]},"reference":[{"key":"2025082701040553000_42.8.57.1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/dtb.1995.331181","article-title":"The drug treatment of patients with schizophrenia","volume":"33","year":"1995","journal-title":"DTB"},{"key":"2025082701040553000_42.8.57.2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/dtb.1997.351181","article-title":"Olanzapine, sertindole and schizophrenia","volume":"35","year":"1997","journal-title":"DTB"},{"key":"2025082701040553000_42.8.57.3","doi-asserted-by":"crossref","unstructured":"Bagnall A-M et al. A systematic review of atypical antipsychotic drugs in schizophrenia Health Technol Assess 2003; 7 13.","DOI":"10.3310\/hta7130"},{"key":"2025082701040553000_42.8.57.4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/bmj.324.7332.250","article-title":"Hyperprolactinaemia caused by antipsychotic drugs","volume":"234","author":"Wieck","year":"2002","journal-title":"BMJ"},{"key":"2025082701040553000_42.8.57.5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/oxfordjournals.schbul.a033315","article-title":"Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort","volume":"24","author":"Wiersma","year":"1998","journal-title":"Schizophr Bull"},{"key":"2025082701040553000_42.8.57.6","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a033315"},{"key":"2025082701040553000_42.8.57.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16458-1"},{"key":"2025082701040553000_42.8.57.8","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.164.2.141"},{"key":"2025082701040553000_42.8.57.9","unstructured":"Clozaril Summary of product characteristics, UK Novartis Pharmaceuticals UK Ltd December 2002."},{"key":"2025082701040553000_42.8.57.10","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2165\/00003495-200262110-00006","article-title":"Antipsychotic-related QTc prolongation, torsade de pointes and sudden death","volume":"62","author":"Haddad","year":"2002","journal-title":"Drugs"},{"key":"2025082701040553000_42.8.57.11","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262110-00006"},{"key":"2025082701040553000_42.8.57.12","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.6.553"},{"key":"2025082701040553000_42.8.57.13","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.7.1209"},{"key":"2025082701040553000_42.8.57.14","unstructured":"National Institute for Clinical Excellence. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. June 2002 [online]. Available: http:\/\/www.nice.org.uk\/pdf\/ANTIPSYCHOTICfinalguidence.pdf [Accessed 21 July 2004]."},{"key":"2025082701040553000_42.8.57.15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/026988110001400411","article-title":"Refractory schizophrenia and atypical antipsychotics","volume":"14","author":"Taylor","year":"2000","journal-title":"J Psychopharmacol"},{"key":"2025082701040553000_42.8.57.16","doi-asserted-by":"publisher","DOI":"10.1177\/026988110001400411"},{"key":"2025082701040553000_42.8.57.17","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.3.414"},{"key":"2025082701040553000_42.8.57.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13306-5"},{"key":"2025082701040553000_42.8.57.19","unstructured":"Zoleptil Summary of product characteristics, UK Knoll Ltd April 2002."},{"key":"2025082701040553000_42.8.57.20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","article-title":"Multiple fixed doses of \"seroquel\" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo","volume":"42","author":"Arvantis","year":"1997","journal-title":"Biol Psychiatry"},{"key":"2025082701040553000_42.8.57.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(97)00190-X"},{"key":"2025082701040553000_42.8.57.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1998.tb10044.x"},{"key":"2025082701040553000_42.8.57.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(96)00392-6"},{"key":"2025082701040553000_42.8.57.24","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.166.6.712"},{"key":"2025082701040553000_42.8.57.25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00004714-199902000-00011","article-title":"Prolactin levels and adverse events in patients treated with risperidone","volume":"19","author":"Kleinberg","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"2025082701040553000_42.8.57.26","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199902000-00011"},{"key":"2025082701040553000_42.8.57.27","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-36391"},{"key":"2025082701040553000_42.8.57.28","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1034\/j.1600-0447.2000.101006416.x","article-title":"Atypical antipsychotics and weight gain - a systematic review","volume":"101","author":"Taylor","year":"2000","journal-title":"Acta Psychiatr Scand"},{"key":"2025082701040553000_42.8.57.29","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2000.101006416.x"},{"key":"2025082701040553000_42.8.57.30","first-page":"41","article-title":"Weight change and atypical antipsychotic treatment in patients with schizophrenia","volume":"62","author":"Jones","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"2025082701040553000_42.8.57.31","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0109"},{"key":"2025082701040553000_42.8.57.32","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.2.596"},{"key":"2025082701040553000_42.8.57.33","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.184.47.s112"},{"key":"2025082701040553000_42.8.57.34","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464070-00003"},{"key":"2025082701040553000_42.8.57.35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7358.243"},{"key":"2025082701040553000_42.8.57.36","unstructured":"Duff G . Atypical antipsychotic drugs and stroke CEM\/CMO\/2004\/1 Committee on Safety of Medicines 2004."},{"key":"2025082701040553000_42.8.57.37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1034\/j.1600-0447.2003.02078.x","article-title":"Antipsychotics and QT prolongation","volume":"107","author":"Taylor","year":"2003","journal-title":"Acta Psychiatr Scand"},{"key":"2025082701040553000_42.8.57.38","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2003.02078.x"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2004.42857","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:04:14Z","timestamp":1756281854000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2004.42857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2004,8,1]]},"published-print":{"date-parts":[[2004,8]]}},"alternative-id":["10.1136\/dtb.2004.42857"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2004.42857","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2004,8]]}}}